Preferred therapies for neovascular age-related macular degeneration.

@article{Lally2012PreferredTF,
  title={Preferred therapies for neovascular age-related macular degeneration.},
  author={David R. Lally and Adam T Gerstenblith and Carl D. Regillo},
  journal={Current opinion in ophthalmology},
  year={2012},
  volume={23 3},
  pages={182-8}
}
PURPOSE OF REVIEW This report reviews the current treatment strategies and the most recent clinical trials in the treatment of neovascular age-related macular degeneration. RECENT FINDINGS The functional and anatomic outcomes achieved in the pivotal ranibizumab trials with monthly injections set the standard for comparison. Since then, various modified dosing regimens with the aim of lessening the treatment burden associated with monthly injections have been investigated. Additionally, level… CONTINUE READING

From This Paper

Topics from this paper.
32 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…